Peer-influenced content. Sources you trust. No registration required. This is HCN.

Annals of Internal MedicineEffectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis

This 70-study meta analysis concludes that the evidence is moderate to high that bisphosphonates and denosumab reduce the risk for hip, vertebral, and other fractures. The evidence is moderate to high that abaloparatide and teriparatide reduce clinical fractures and radiographic vertebral fractures, and low to moderate that SERMs reduce radiographic vertebral fractures, but not clinical fractures.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form